Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of INC280/buparlisib resulted in no clear activity in patients with recurrent PTEN-deficient glioblastoma.
|
31776899 |
2020 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with everolimus decreases MCL-1 in colorectal carcinomas and small cell lung cancer (SCLC) cells but not glioblastoma multiforme (GBM) cells with a PTEN mutational background.
|
30201826 |
2019 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also identified protein signatures for GBMs with genetic alterations (IDH mutation, p53 mutation, EGFR amplification or mutation, CDKN2A/CDKN2B deletion, and PTEN mutation) that occur at high frequency.
|
30401645 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, miR-29a robustly promotes invasion in PTEN-deficient glioblastoma cells by repressing translation of the Sox4 transcription factor, and this upregulates the invasion-promoting protein, HIC5.
|
30683134 |
2019 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol‑3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resistance.
|
30942445 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
GBM tumors with concurrent EGFR amplification and active phosphatase and tensin homolog (PTEN) are sensitive to the tyrosine kinase inhibitor erlotinib, but the effect is not durable.
|
31352310 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) deficiency in primary human glioblastoma (GBM) is associated with increased invasiveness and poor prognosis with unknown mechanisms.
|
30357833 |
2019 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, neither PTEN nor EGFR mutation, which is frequently present in glioblastoma, was detected.
|
30496796 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
This symbiotic glioma-macrophage interplay provides therapeutic targets specifically for PTEN-deficient GBM.
|
31185211 |
2019 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analyses of human glioblastoma specimens reveals that PGK1 Y324 phosphorylation levels inversely correlate with PTEN expression status and are positively associated with poor prognosis in glioblastoma patients.
|
31492635 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
NGI-1 sensitizes multiple models of GBM to chemotherapy and radiation <i>in vitro</i> and <i>in vivo</i> and may be especially effective in GBMs that retain active PTEN.<i>See related article by Baro et al., p. 784</i>.
|
30181388 |
2019 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genomic sequencing revealed that the spheroid lines contain alterations in GBM driver genes such as PTEN, CDKN2A, and NF1.
|
30289729 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both PTEN-deficient (U-251) and PTEN-containing (LN229) glioblastoma cells showed a decrease in cell migration velocity in response to SKIP downregulation.
|
30695232 |
2019 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to establish a radiomic signature to predict PTEN mutation status in patients with glioblastoma, and to investigate the genetic background behind this radiomic signature.
|
31218383 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gain-of-function and loss-of-function studies indicated that PTEN enhanced the sensitivity of GBM cells to palbociclib <i>in vitro</i> and <i>in vivo</i>, which was associated with suppressions of Akt and ERK signaling and independent of Rb signaling inhibition.
|
31787897 |
2019 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
|
31243804 |
2019 |
Glioblastoma Multiforme
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To identify transcriptomic profiles associated with a hyperactivated PI3K pathway, RNA-sequencing analysis was performed in a glioblastoma cell line stably expressing PTEN.
|
29729901 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
We generated 3 PARPi-resistant PTEN-deficient glioblastoma U251 variants separately with olaparib (U251/OP), talazoparib (U251/TP) and simmiparib (U251/SP).
|
29274141 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibitory effect on GBM cell proliferation is independent of PTEN status.
|
29886836 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.
|
29799523 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our findings support that NQO1 displays a paradoxical role in mediating GBM growth in response to tumor suppressor PTEN.
|
30595797 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status.
|
29209894 |
2018 |
Glioblastoma Multiforme
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes.
|
29444555 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth.
|
29941984 |
2018 |
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway has emerged as a crucial player in GBM development and progression.
|
30662577 |
2018 |